Skip to main content
Log in

Do 2-amino-3,8-dimethylimidazo[4,5-f] quinoxaline data support the conclusion of threshold carcinogenic effects?

  • Original Paper
  • Published:
Stochastic Environmental Research and Risk Assessment Aims and scope Submit manuscript

Abstract

The objectives of this paper are to (1) reexamine the data that were used to support the conclusion of a threshold effect for 2-amino-3,8-dimethylimidazo[4,5-f] quinoxaline (MeIQx)-induced initiation and carcinogenicity at low doses in the rat liver, and (2) discuss issues and uncertainties about assessing cancer risk at low doses. Our analysis is part of an effort to understand proper interpretation and modeling of data related to cancer mechanisms and is not an effort to develop a risk assessment for this compound. The data reanalysis presented herein shows that the low-dose initiation activity of MeIQx, which can be found in cooked meat, cannot be dismissed. It is argued that the threshold effect for carcinogenic agents cannot be determined by statistical non-significance alone; more relevant biological information is required. A biologically motivated procedure is proposed for data analyses. The concept and procedure that are appropriate for analyzing MeIQx data are equally applicable to other compounds with comparable data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  • Andersen M, Barton H (1998) The use of biochemical and molecular parameters to estimate dose–response relationships at low levels of exposure. Environ Health Perspect 106(Suppl 1):349–355

    Article  CAS  Google Scholar 

  • Anderson K, Kadlubar F, Kulldorff M, Harnack L, Gross M, Lang N, Barber C, Rothman N, Sinha R (2005) Dietary intake of heterocyclic amines and benzo(a)pyrene: associations with pancreatic cancer. Cancer Epidemiol Biomarkers Prev 14:2261–2265

    Article  CAS  Google Scholar 

  • Chen C, Farland W (1991) Incorporating cell proliferation in quantitative cancer risk assessment: approaches, issues, and uncertainties. In: Butterworth B, Slaga T, Farland W, McClain M (eds) Chemically induced cell proliferation: implication for risk assessment. Proceedings of the chemically induced cell proliferation conference, Austin, TX, 29 November–2 December, 1989, Wiley-Liss, New York, pp 481–499

  • Chen C, Moini A (1990) Cancer dose–response models with clonal expansion. In: Moolgavkar SH (ed) Scientific issues in quantitative cancer risk assessment. Birkhäuser, Boston, pp 153–175

    Google Scholar 

  • Chen C, Gibb H, Moini A (1991) Models for analyzing data in initiation–promotion studies. Environ Health Perspect 90:287–292

    Article  CAS  Google Scholar 

  • Cohen S, Ellwein L (1990) Proliferative and genotoxic cellular effects in 2-acetylaminofluorene bladder and liver carcinogenesis: biological modeling of the ED01 study. Toxicol Appl Pharmacol 104:79–93

    Article  CAS  Google Scholar 

  • Dolijanski F (1960) The growth of the liver with special reference to mammals. Int Rev Cytol 10:217–241

    Google Scholar 

  • Frantz C, Bangerter C, Fultz E, Mayer K, Vogel J, Turteltaub K (1995) Dose–response studies of MeIQx in rat liver and liver DNA at low doses. Carcinogenesis 16:367–373

    Article  CAS  Google Scholar 

  • Fukushima S, Wanibuchi H, Morimura K, Wei M, Nakae D, Konishi Y, Tsuda H, Uehara N, Imaida K, Shirai T, Tatematsu M, Tsukamoto T, Hirose M, Furukawa F, Wakabayashi K, Totsuka Y (2002) Lack of a dose–response relationship for carcinogenicity in the rat liver with low doses of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline or N-nitrosodiethylamine. Jpn J Cancer Res 93:1076–1082

    CAS  Google Scholar 

  • Fukushima S, Wanibuchi H, Morimura K, Wei M, Nakae D, Konishi Y, Tsuda H, Takasuka N, Imaida K, Shirai T, Tatematsu M, Tsukamoto T, Hirose M, Furukawa F (2003) Lack of initiation activity in rat liver of low doses of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline. Cancer Lett 191:35–40

    Article  CAS  Google Scholar 

  • Garner R, Lightfoot T, Cupid B, Russell D, Coxhead J, Kutschera W, Priller A, Rom W, Steier P, Alexander D, Leveson S, Dingley K, MautheJ, Turteltaub K (1999) Comparative biotransformation studies of MeIQx and PhIP in animal models and humans. Cancer Lett 143:161–165

    Article  CAS  Google Scholar 

  • Ginsberg G, Smolenski S, Hattis D, Sonawane B (2002) Population distribution of aldehyde dehydrogenase-2 genetic polymorphism: implications for risk assessment. Regul Toxicol Pharmacol 36:297–309

    Article  CAS  Google Scholar 

  • Grasl-Kraupp B, Luebeck G, Wagner A, Low-Baselli A, de Gunst M, Waldhor T, Moolgavkar S, Schulte-Hermann R (2000) Quantitative analysis of tumor initiation in rat liver: role of cell replication and cell death (apoptosis). Carcinogenesis 21:1411–1421

    Article  CAS  Google Scholar 

  • Hein D, Fretland A, Doll M (2006) Effects of single nucleotide polymorphisms in human N-acetyltransferase-2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens. Int J Cancer 119:1208–1211

    Article  CAS  Google Scholar 

  • Holsapple M, Pitot H, Cohen S, Boobis A, Klaunig J, Pastoor T, Dellarco V, Dragan Y (2006) Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci 89:51–56

    Article  CAS  Google Scholar 

  • Hoshi M, Morimura K, Wanibuchi H, Wei M, Okochi E, Ushijima T, Takaoka K, Fukushima S (2004) No-observed effect levels for carcinogenicity and for in vivo mutagenicity of a genotoxic carcinogen. Toxicol Sci 81:273–279

    Article  CAS  Google Scholar 

  • International Programme on Chemical Safety (1999) Principles for the assessment of risks to human health from exposure to chemicals. Environmental Health Criteria 210

  • Ishibe N, Sinha R, Hein D, Kulldorff M, Strickland P, Fretland A, Chow W, Kadlubar F, Lang N, Rothman N (2002) Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics 12:145–150

    Article  CAS  Google Scholar 

  • Kolaja K, Stevenson D, Walborg E, Klaunig J (1996) Dose dependence of phenobarbital promotion of preneoplastic hepatic lesions in F344 rats and B6C3F1 mice: effects on DNA synthesis and apoptosis. Carcinogenesis 17:947–954

    Article  CAS  Google Scholar 

  • Lutz R, Stahel W, Lutz W (2002) Statistical procedure to test for linearity and estimate threshold doses for tumor induction with non-linear dose–response relationships in bioassays for carcinogenicity. Regul Toxicol Pharmacol 36:331–337

    Article  CAS  Google Scholar 

  • Lutz W, Gaylor D, Conolly R, Lutz R (2005) Nonlinearity and thresholds in dose–response relationships for carcinogenicity due to sampling variation, logarithmic dose scaling, or small differences in individual susceptibility. Toxicol Appl Pharmacol 207:565–569

    Article  CAS  Google Scholar 

  • Maronpot R, Foley J, Takahashi K, Goldsworthy T, Clark G, Tritscher A, Portier C, Lucier G (1993) Dose response for TCDD promotion of hepatocarcinogenesis in rats initiated with DEN: histologic, biochemical, and cell proliferation endpoints. Environ Health Perspect 101:634–642

    Article  CAS  Google Scholar 

  • Mauthe R, Dingley K, Leveson S, Freeman S, Turesky R, Garner R, Turteltaub K (1999) Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low dose. Int J Cancer 80:539–545

    Article  CAS  Google Scholar 

  • Melnick R, Kohn M, Portier C (1996) Implications for risk assessment of suggested nongenotoxic mechanisms of chemical carcinogenesis. Environ Health Perspect 104(Suppl 1):123–134

    Article  CAS  Google Scholar 

  • Moolgavakar S, Luebeck E, de Gunst M, Port R, Schwarz M (1990) Quantitative analysis of enzyme-altered foci in rat hepatocarcinogenesis experiments—I. Single agent regimen Carcinogenesis 11:1271–1278

    Article  Google Scholar 

  • Moore M, Nakagawa K, Satoh K, Ishikawa T, Sato K (1987) Single GST-P positive liver cells—putative initiated hepatocytes. Carcinogenesis 8:483–486

    Article  CAS  Google Scholar 

  • Pitot H (1990) Altered hepatic foci: their role in murine hepatocarcinogenesis. Annu Rev Pharmacol Toxicol 30:465–500

    Article  CAS  Google Scholar 

  • Rovito P, Morse P, Spinek K, Newman N, Jones R, Wang C, Haas G (2005) Heterocyclic amines and genotype of N-acetyltransferases as risk factors for prostate cancer. Prostate Cancer Prostatic Dis 8:69–74

    Article  CAS  Google Scholar 

  • Sinha R, Kulldorff M, Swanson C, Curtin J, Brownson R, Alavanja M (2000) Dietary heterocyclic amines and the risk of lung cancer among Missouri women. Cancer Res 60:3753–3756

    CAS  Google Scholar 

  • Sinha R, Kulldorff M, Chow W, Denobile J, Rothman N (2001) Dietary intake of heterocyclic amines, meat-derived mutagenic activity, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 10:559–562

    CAS  Google Scholar 

  • Solomon M, Morgenthaler P, Turesky R, Essigmann J (1996) Mutational and DNA binding specificity of the carcinogen 2-amino-3, 8-dimethylimidazo[4,5-f]quinoxaline. J Biol Chem 271:18368–18374

    Article  CAS  Google Scholar 

  • Tritscher A (2004) Human health risk assessment of processing-related compounds in food. Toxicol Lett 149:177–186

    Article  CAS  Google Scholar 

  • Turesky R, Garner R, Welti D, Richoz J, Leveson S, Dingley, Turteltaub K, Fay L (1998) Metabolism of the food-borne mutagen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in humans. Chem Res Toxicol 11:217–225

    Article  CAS  Google Scholar 

  • Turteltaub K, Mauthe R, Dingley K, Vogel J, Frantz C, Garner R, Shen N (1997) MeIQx-DNA adduct formation in rodent and human tissues at low doses. Mutat Res 376:243–252

    CAS  Google Scholar 

  • USEPA Guidelines for carcinogen risk assessment and supplemental guidance for assessing susceptibility from early-life exposure to carcinogens (2005) Federal Register 70(66):17765–17817, 4 July, 2005

    Google Scholar 

  • Wei M, Hori T, Ichihara T, Wanibuchi H, Morimura K, Kang J, Puatanachokchai R, Fukushima S (2006) Existence of no-observed effect levels for 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline on hepatic preneoplastic lesion development in BN rats. Cancer Lett 231:304–308

    Article  CAS  Google Scholar 

  • Yamashita K, Adachi M, Kato S, Nakagama H, Ochiai M, Wakabayashi K, Sato S, Nagao M, Sugimura T (1990) DNA adducts formed by 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in rat liver: dose–response on chronic administration. Jpn J Cancer Res 81:470–476

    CAS  Google Scholar 

  • Zeise L, Wilson R, Crouch E (1987) Dose–response relationships for carcinogens: a review. Environ Health Perspect 73:259–306

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Paul White for helpful comments that lead to improvement of the paper.

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chao Chen.

Additional information

The ideas and approaches in this presentation are those of the authors and do not necessarily represent the positions or policies of the USEPA.

Appendix

Appendix

The following brief derivation is taken from Chen et al. (1991) for modeling initiation–promotion data. A generalization of the same tumor development concept can be found in Chen and Farland (1991). This approach uses the same concept of carcinogenesis modeling in Cohen and Ellwein (1990) in which mitotic rate is explicitly introduced in the model. The advantage of modeling by mitotic rate is that some information on mitotic rate is available; these data can be used as prior information in the Bayesian analysis.

1.1 Basic assumptions

(1) At time t = 0, a normal cell has a probability μ 1 of being initiated to become an I-cell;

(2) Each I-cell has a random lifetime (i.e., time to mitosis) with a probability density function f(t);

(3) At mitosis, an I-cell is subjected to a homogenous birth and death process with probability of birth and death, given respectively by b and d with b + d = 1; and

(4) All I-cells go through this process independently of each other.

Under the assumption that cell lifetime is exponentially distributed with parameter λ [i.e., f(t) = λexp(−λt)], the probability that a focus has size k at time t is given by

$$ P_{k} (t) = [1 - P_{0} (t)][1 - A(t)][A(t)]^{{k - 1}} ,\quad k \ge 1 $$
(3)

where

$$ B(t) = \frac{{1 - \exp (gt)}} {{1 - r\exp (gt)}};\quad g = \lambda (b - d);\;r = b/d; $$

and A(t) = rB(t).

The reciprocal, 1/λ, of the parameter λ can be interpreted as the mean time to mitosis, or equivalently, λ can be interpreted as mean mitotic rate.

If we assume that a focus becomes detectable when it contains at least s cells, then the probability for a focus to be countable is

$$ D_{s} (t) = {\sum\limits_{k = s} {P_{k} (t)} } = [1 - B(t)][A(t)]^{{s - 1}} $$
(4)

Eq. (4) is the basic formula to construct a time dependent piece-wise constant model used in the simulation.

The advantage of considering random cell-lifetime in formulating the initiation and growing process of foci is that available biological information, as discussed above, can be readily incorporated and it is more realistic to assume that cell lifespan is random, rather than assuming that all cells enter the mitotic phase at the same time; this is a feature particularly suitable for Bayesian analysis.

1.2 Piece-wise constant model

To allow for partial lifetime exposure, we divide the animal lifetime in the IP study into three subintervals: (0, 20), (21, 49), and (50, 133) in days. This represents the experimental conditions that animals were 3 weeks (21 days) old when they were first received MeIQx for 4 weeks followed by PB for 11 weeks. The general concept to construct a model with piece-wise constant parameters for Bayesian analysis is based on the fact that the number of initiated cells, I(t), at any giving time t, is a Poisson process (Chen and Moini 1990), and the fact that the expected number of I-cells at any time t, getting initiated at t 0, is I(t) = I(t 0) exp(g(t − t 0)) where g = b − d is the net growth rate for an I-cell. In the piece-wise constant model g is allowed to vary over different time intervals. Using this concept, the number of I-cells available at the beginning of the last sub-interval (50, 133) can be calculated. The number of foci of a particular size can be computed using Eqs. (3) and (4).

The model can be computed using the free software WinBugs as described in the text. In this model, the number of normal cells per cm2 is assumed to be N = 600,000. It should be noted that accuracy of N is not required because 1 occurred as a term in the model and μ 1 is estimated from data; under-specification of N will be compensated for by the higher estimated value μ 1 and vice versa. For the dose group k at age t, as specified in the model, the parameter μ 1 is assumed to be linearly related to dose μ 1[k, t] = μ 10 + μ 11 dose_MQ[k, t] and the mean mitotic rate is given by mt[k, t] = (1 − exp[−(mt 0 + mt 1 dose 1[k, t] + mt 2 dose 2[t])]) where mt 0 is the background mitotic rate, mt 1 and mt 2 are, respectively, coefficients for the MeIQx (dose 1) and the PB (dose 2) doses. In order to assign a reasonable non-informative, some knowledge about these parameters are needed. Some mitosis data can be found in Cohen and Ellwein (1990) and others. A wide range, from 1.0E-5 to 1.0E-2, of mitotic rate for the normal cells is also reported in Dolijanski (1960). Although the precise magnitude of mitotic rate for the MeIQX-induced initiated cells is not known, this information is useful for setting the upper bound for the non-informative prior in the Bayesian analysis. In all of the calculations, b 0 = 0.501 is used. The value for b 0 is obtained by perturbation of its value upward from 0.50 to find the best fit of data from the non-IP data in Table 1. Note that this is considered part of the process of using the non-IP data for summarizing and synthesizing information coming from various sources with different quality; the objective is to find a set of parameters that adequately fit the data. Ultimately, the conclusion comes from the more rigorous analysis of the IP-data.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, C., Guyton, K.Z. Do 2-amino-3,8-dimethylimidazo[4,5-f] quinoxaline data support the conclusion of threshold carcinogenic effects?. Stoch Environ Res Risk Assess 22, 487–494 (2008). https://doi.org/10.1007/s00477-007-0150-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00477-007-0150-1

Keywords

Navigation